Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Menopausal hormone therapy linked to greater weight loss with tirzepatide

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity.

22 Jan 2026

GLP-1 weight-loss drugs show early promise for treating addiction

This systematic review evaluates preclinical and clinical evidence on glucagon-like peptide-1 receptor agonists as potential treatments for substance use disorders. Findings show consistent reductions in drug- and alcohol-seeking behaviors in animal models, while human evidence remains limited, heterogeneous, and preliminary.

21 Jan 2026

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction-associated steatohepatitis (MASH), represent the most common chronic liver diseases in Western populations, driven largely by obesity and insulin resistance.

21 Jan 2026

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Bariatric surgery and GLP-1 treatments reshape body composition differently, emphasizing the importance of sex and treatment choice in muscle preservation.

14 Jan 2026

Most patients regain lost weight within two years of stopping obesity drugs

Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need for sustainable obesity strategies.

13 Jan 2026

Why adherence determines weight loss success with semaglutide

Researchers examine how the effectiveness of weight-loss medications may depend on the patient adherence.

12 Jan 2026

Weight loss drugs and surgery improve body composition in patients with obesity

Both the new weight loss drugs and bariatric (weight loss) surgery improve body composition in patients with obesity by inducing a moderate loss of fat-free mass (including lean muscle) along with a substantial reduction in fat, researchers at Vanderbilt Health have found.

9 Jan 2026

California ends Medicaid coverage of weight loss drugs despite TrumpRx plan

Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year.

9 Jan 2026

Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK

In early 2025, around 4.9 million British adults - almost one in ten - are estimated to have recently used, or expressed interest in using, glucagon-like peptide-1 (GLP-1) or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist medications to support weight loss. The findings, which are based on a nationally representative household survey of 5,260 British adults, are published in BMC Medicine.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Millions in Great Britain using or seeking weight loss drugs

An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.

7 Jan 2026

Stopping weight loss drugs leads to rapid weight regain and health reversal

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published by The BMJ today.

7 Jan 2026

How GLP‑1 agonists are shaping the future of obesity treatment with Dr Bryony Henderson

GLP-1 agonists are pivotal in obesity care, promoting weight loss and addressing related health issues, with a focus on personalized, holistic treatment.

23 Dec 2025

Fatty diets reprogram hepatocytes and increase liver cancer risk

One of the biggest risk factors for developing liver cancer is a high-fat diet. A new study from MIT reveals how a fatty diet rewires liver cells and makes them more prone to becoming cancerous.

22 Dec 2025

Glucose-lowering drugs may reduce risk of developing epilepsy

A preliminary study of people with diabetes suggests that use of glucose-lowering GLP-1 drugs may be linked to a lower risk of developing epilepsy. The study was published on December 10, 2025, in Neurology, the medical journal of the American Academy of Neurology.

10 Dec 2025

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Researchers profiled a terminally sterilized probiotic-fermented MFH beverage and identified aporphine alkaloids and flavonoids with favorable predicted ADMET properties. Integrated network pharmacology, molecular docking, and 100-ns MD simulations suggest multi-target engagement of metabolic-inflammatory pathways relevant to obesity and type 2 diabetes.

9 Dec 2025

Sudden cardiac death risk is sharply elevated in people with diabetes

The risk of sudden cardiac death is higher both for people with type 1 and type 2 diabetes, according to a large study published in the European Heart Journal today (Thursday). The increase in risk is especially noticeable among younger adults.

3 Dec 2025

Diabetes drugs linked to slower frailty progression in older adults

A new study shows that older adults with type 2 diabetes who start treatment with sodium–glucose cotransporter-2 (SGLT-2) inhibitors-such as empagliflozin (Jardiance) and dapagliflozin (Farxiga)-or glucagon-like peptide-1 (GLP-1) receptor agonists-such as semaglutide (Ozempic) and liraglutide (Victoza)-experience slower progression of frailty over one year compared with those starting other diabetes medications.

3 Dec 2025

Obesity-driven estrone emerges as a key driver of deadly postmenopausal breast cancer

A new analysis of research into the most common type of breast cancer has zeroed in on an overlooked hormone that may be responsible for the increased risk of breast cancer death in post-menopausal women with obesity.

2 Dec 2025

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

To address the growing global health challenge of obesity, which affects more than 1 billion people, the World Health Organization (WHO) has released its first guideline on the use of Glucagon-Like Peptide-1 (GLP-1) therapies for treating obesity as a chronic, relapsing disease.

2 Dec 2025

Semaglutide

Overview

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Latest Semaglutide News and Research

Menopausal hormone therapy linked to greater weight loss with tirzepatide

GLP-1 weight-loss drugs show early promise for treating addiction

NuSHs can be a promising therapeutic strategy for preventing MASH-related hepatocellular carcinoma

Bariatric surgery reshapes body fat and muscle more than GLP-1 drugs

Most patients regain lost weight within two years of stopping obesity drugs

Why adherence determines weight loss success with semaglutide

Weight loss drugs and surgery improve body composition in patients with obesity

California ends Medicaid coverage of weight loss drugs despite TrumpRx plan

Study highlights prevalence of GLP-1/GIP medication use for weight loss in UK

Weight loss drugs may cause nutritional deficiencies without proper guidance

Millions in Great Britain using or seeking weight loss drugs

Stopping weight loss drugs leads to rapid weight regain and health reversal

How GLP‑1 agonists are shaping the future of obesity treatment with Dr Bryony Henderson

Fatty diets reprogram hepatocytes and increase liver cancer risk

Glucose-lowering drugs may reduce risk of developing epilepsy

Sterilized fermented beverage targets obesity and type 2 diabetes pathways in computational study

Sudden cardiac death risk is sharply elevated in people with diabetes

Diabetes drugs linked to slower frailty progression in older adults

Obesity-driven estrone emerges as a key driver of deadly postmenopausal breast cancer

WHO releases first guideline on the use of GLP-1 therapies for treating obesity

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Semaglutide

Overview

Latest Semaglutide News and Research

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Newsletters you may be interested in